As the founding CEO of FDNA, Dekel Gelbman leads the corporate and business strategy of a digital health company that develops artificial intelligence technologies and SaaS platforms used by thousands of clinical, research, and lab sites globally in the clinical genomics space. FDNA has created a new gold-standard—next-generation phenotyping (NGP)—technologies that capture, structure, and analyze complex human physiological data to produce actionable genomic insights from next-generation sequencing data. Since it’s founding, FDNA has positioned itself at the forefront of AI, genomics, and personalized medicine.
Prior to joining FDNA, Mr. Gelbman was a practicing corporate and transactional attorney working for leading law firms, including among others, Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates. Mr. Gelbman’s experience includes working closely with a variety of technology and biotech companies, at all stages, from startups through growth stage companies, and to mature, publicly-traded companies. He holds an LL.B and an MBA in finance.